FGIN-1-27 Inhibits Melanogenesis by Regulating Protein Kinase A/cAMP-Responsive Element-Binding, Protein Kinase C-β, and Mitogen-Activated Protein Kinase Pathways

FGIN-1-27 is a synthetic mitochondrial diazepam binding inhibitor receptor (MDR) agonist that has demonstrated pro-apoptotic, anti-anxiety, and steroidogenic activity in various studies. Here we report, for the first time, the anti-melanogenic efficacy of FGIN-1-27 in vitro and in vivo. FGIN-1-27 si...

Full description

Saved in:
Bibliographic Details
Main Authors: Jinpeng Lv (Author), Songzhou Jiang (Author), Ying Yang (Author), Ximei Zhang (Author), Rongyin Gao (Author), Yan Cao (Author), Guoqiang Song (Author)
Format: Book
Published: Frontiers Media S.A., 2020-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a103513bec2f487ca5df02c7bcd9e86a
042 |a dc 
100 1 0 |a Jinpeng Lv  |e author 
700 1 0 |a Songzhou Jiang  |e author 
700 1 0 |a Ying Yang  |e author 
700 1 0 |a Ximei Zhang  |e author 
700 1 0 |a Rongyin Gao  |e author 
700 1 0 |a Yan Cao  |e author 
700 1 0 |a Guoqiang Song  |e author 
245 0 0 |a FGIN-1-27 Inhibits Melanogenesis by Regulating Protein Kinase A/cAMP-Responsive Element-Binding, Protein Kinase C-β, and Mitogen-Activated Protein Kinase Pathways 
260 |b Frontiers Media S.A.,   |c 2020-12-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2020.602889 
520 |a FGIN-1-27 is a synthetic mitochondrial diazepam binding inhibitor receptor (MDR) agonist that has demonstrated pro-apoptotic, anti-anxiety, and steroidogenic activity in various studies. Here we report, for the first time, the anti-melanogenic efficacy of FGIN-1-27 in vitro and in vivo. FGIN-1-27 significantly inhibited basal and α-melanocyte-stimulating hormone (α-MSH)-, 1-Oleoyl-2-acetyl-sn-glycerol (OAG)- and Endothelin-1 (ET-1)-induced melanogenesis without cellular toxicity. Mushroom tyrosinase activity assay showed that FGIN-1-27 did not directly inhibit tyrosinase activity, which suggested that FGIN-1-27 was not a direct inhibitor of tyrosinase. Although it was not capable of modulating the catalytic activity of mushroom tyrosinase in vitro, FGIN-1-27 downregulated the expression levels of key proteins that function in melanogenesis. FGIN-1-27 played these functions mainly by suppressing the PKA/CREB, PKC-β, and MAPK pathways. Once inactivated, it decreased the expression of MITF, tyrosinase, TRP-1, TRP-2, and inhibited the tyrosinase activity, finally inhibiting melanogenesis. During in vivo experiments, FGIN-1-27 inhibited the body pigmentation of zebrafish and reduced UVB-induced hyperpigmentation in guinea pig skin, but not a reduction of numbers of melanocytes. Our findings indicated that FGIN-1-27 exhibited no cytotoxicity and inhibited melanogenesis in both in vitro and in vivo models. It may prove quite useful as a safer skin-whitening agent. 
546 |a EN 
690 |a FGIN-1-27 
690 |a human epidermis melanocytes 
690 |a SK-MEL-2 cells 
690 |a melanogenesis 
690 |a protein kinase A/cAMP-responsive element-binding 
690 |a protein kinase C-β 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 11 (2020) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2020.602889/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/a103513bec2f487ca5df02c7bcd9e86a  |z Connect to this object online.